select a format

Single User License
USD 300 INR 19227
Site License
USD 600 INR 38454
Corporate User License
USD 900 INR 57681

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Mesoblast Limited (MSB)-Financial and Strategic SWOT Analysis Review

Mesoblast Limited (MSB)-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH61698FSA
  • |
  • Pages: 53
  • |
  • August 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Mesoblast Limited (MSB)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Mesoblast Limited (Mesoblast) is a regenerative medicine company, which develops regenerative cell-based products. Its pipeline product candidates include MPC-150-IM, which is under development for the treatment of chronic congestive heart failure; MSC-100-IV, for the treatment of acute graft versus host disease; MPC-06-ID, for the treatment of chronic low back pain (CLBP); and MPC-300-IV for the treatment of chronic inflammatory conditions such as biologic-refractory rheumatoid arthritis, and diabetic nephropathy. Mesoblast conducts clinical trials in various areas such as cardiac diseases, spinal orthopedic disorders, cancer, hematological conditions, and immune-mediated and inflammatory conditions. The company has operational presence in the US and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.

Mesoblast Limited Key Recent Developments

Aug 25, 2016: Mesoblast Reports Financial Results And Operational Highlights For The Three Months And For The Year Ended 30 June 2016

Aug 17, 2016: Mesoblast Strengthens Key United States Patent Portfolio For the Treatment Of Rheumatic Diseases

May 20, 2016: Mesoblast Receives $6.2 Million From Australian Government For Research And Development Activities

May 09, 2016: Mesoblast Reports Financial Results For Period Ended 31 March 2016 And Provides Corporate Update

Mar 24, 2016: Key United States Patent Granted For Cell-Based Treatment Of Rheumatoid Arthritis And Other Rheumatic Conditions

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

Mesoblast Limited-Key Facts 6

Mesoblast Limited-Key Employees 7

Mesoblast Limited-Key Employee Biographies 8

Mesoblast Limited-Major Products and Services 9

Mesoblast Limited-Pharmaceutical Pipeline Products Data 10

Mesoblast Limited, Pipeline Products by Therapy Area 10

Mesoblast Limited, Pipeline Products by Development Phase 11

Mesoblast Limited-History 13

Mesoblast Limited-Company Statement 15

Mesoblast Limited-Locations And Subsidiaries 16

Head Office 16

Other Locations & Subsidiaries 16

Section 2-Company Analysis 17

Mesoblast Limited-Business Description 17

Mesoblast Limited-Corporate Strategy 18

Mesoblast Limited-SWOT Analysis 19

SWOT Analysis-Overview 19

Mesoblast Limited-Strengths 19

Strength-Focused Research and Development Activities 19

Strength-Strong Collaborations 19

Strength-Proprietary Technology 19

Mesoblast Limited-Weaknesses 20

Weakness-High Costs 20

Mesoblast Limited-Opportunities 21

Opportunity-Agreement with Celgene Corporation 21

Opportunity-Changing Demographics 21

Opportunity-Increasing Healthcare Expenditure in the US 21

Mesoblast Limited-Threats 22

Threat-Uncertain R&D Outcomes 22

Threat-Competitive Pressures 22

Threat-Stringent Government Regulations 22

Mesoblast Limited-Key Competitors 23

Section 3-Company Financial Ratios 24

Financial Ratios-Annual Ratios 24

Performance Chart 25

Financial Performance 25

Financial Ratios-Interim Ratios 26

Financial Ratios-Ratio Charts 27

Section 4-Company's Lifesciences Financial Deals and Alliances 28

Mesoblast Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 28

Mesoblast Limited, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 29

Mesoblast Limited, Recent Deals Summary 30

Section 5-Company's Recent Developments 31

Aug 25, 2016: Mesoblast Reports Financial Results And Operational Highlights For The Three Months And For The Year Ended 30 June 2016 31

Aug 17, 2016: Mesoblast Strengthens Key United States Patent Portfolio For the Treatment Of Rheumatic Diseases 35

May 20, 2016: Mesoblast Receives $6.2 Million From Australian Government For Research And Development Activities 37

May 09, 2016: Mesoblast Reports Financial Results For Period Ended 31 March 2016 And Provides Corporate Update 38

Mar 24, 2016: Key United States Patent Granted For Cell-Based Treatment Of Rheumatoid Arthritis And Other Rheumatic Conditions 41

Feb 16, 2016: Mesoblast Reports on First Half and Second Quarter Financial Results 42

Dec 16, 2015: Mesoblast Provides Strategic Update and Reports on First Quarter Financial Results 44

Nov 23, 2015: Mesoblast Investor Update 46

Nov 15, 2015: Mesoblast Lists On Nasdaq 47

Oct 27, 2015: Key United States Patent Granted For The Treatment Of Heart Diseases, Stroke And Other Vascular Conditions 48

Section 6-Appendix 49

Methodology 49

Ratio Definitions 49

About GlobalData 53

Contact Us 53

Disclaimer 53

List of Figures

Mesoblast Limited, Pipeline Products by Therapy Area 10

Mesoblast Limited, Pipeline Products by Development Phase 11

Mesoblast Limited, Performance Chart (2012-2016) 25

Mesoblast Limited, Ratio Charts 27

Mesoblast Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 28

Mesoblast Limited, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 29

List of Tables

Mesoblast Limited, Key Facts 6

Mesoblast Limited, Key Employees 7

Mesoblast Limited, Key Employee Biographies 8

Mesoblast Limited, Major Products and Services 9

Mesoblast Limited, Number of Pipeline Products by Therapy Area 10

Mesoblast Limited, Number of Pipeline Products by Development Stage 11

Mesoblast Limited, Pipeline Products By Therapy Area and Development Phase 12

Mesoblast Limited, History 13

Mesoblast Limited, Subsidiaries 16

Mesoblast Limited, Key Competitors 23

Mesoblast Limited, Annual Ratios 24

Mesoblast Limited, Interim Ratios 26

Mesoblast Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 28

Mesoblast Limited, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 29

Mesoblast Limited, Recent Deals Summary 30

Currency Codes 49

Capital Market Ratios 49

Equity Ratios 50

Profitability Ratios 50

Cost Ratios 51

Liquidity Ratios 51

Leverage Ratios 52

Efficiency Ratios 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Mesoblast Limited, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com